A Phase 3 interventional study of Fumaric Acid Esters and Methotrexate in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 21 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-09.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 11th largest by enrollment, is one of 3 that started in 2016, is one of 11 in phase 3, and was the 10th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 162 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 19th largest by enrollment, is one of 5 that started in 2016, is one of 15 in phase 3, and was the 14th registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy of ixekizumab compared to fumaric acid esters (FAE) and methotrexate (MTX) in participants with moderate-to-severe plaque psoriasis who are naive to systemic treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24. Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks.
Drug: Ixekizumab
Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24. Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks.
Drug: Fumaric Acid Esters · Drug: Ixekizumab
7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24. Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks.
Drug: Methotrexate · Drug: Ixekizumab
Administered orally
Administered orally
Administered SC
Also known as: LY2439821
Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) at Week 24
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Week 24
Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Week 24
Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100) From Baseline
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
Time frame: Week 24
Change From Baseline in PASI Total Score
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). LS mean change from baseline in PASI was calculated using Analysis of Covariance (ANCOVA) with modified Baseline- Observation- Carried Forward (mBOCF) and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) and ≥2 Point Improvement From Baseline Among Those With sPGA Score ≥3 at Baseline
The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
Time frame: Week 24
Percentage of Participants Achieving DLQI (0,1)
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5-point change from baseline is considered clinically relevant.
Time frame: Week 24
Change From Baseline on Dermatology Life Quality Index (DLQI) Total Score
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5-point change from baseline is considered clinically relevant. LS mean change from baseline in DLQI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis
The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) Total Score
The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS mean change from baseline in PPASI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Total Score
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS mean change from baseline in PSSI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Patient Benefit Index (PBI) Overall Benefit Score
The PBI assessment consists of 2 steps: before treatment, every patient defines his/her treatment needs according to a standardized list (Patient Needs Questionnaire \[PNQ\]). After treatment, the patient rates the degree of benefits achieved (Patient Benefits Questionnaire \[PBQ\]). 25 items are rated on a 5-point scale with values from 0 (not at all) to 4 (very), allowing for "did not apply to me" (5) and missing. For each treatment goal the PNQ importance is derived by dividing the respective PNQ item by the sum of all PNQ items. The weighted sum of each PBQ item with its respective PNQ importance yields the PBI score. LS mean was calculated using ANCOVA with LOCF and with a term for treatment.
Time frame: Week 24
Change From Baseline on Itch Numeric Rating Scale (NRS) Score
The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis (Ps) is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline on the Skin Pain Visual Analog Scale (VAS)
The pain VAS is a participant-administered single-item scale designed to measure Skin pain from Psoriasis using a 100 millimeter (mm) horizontal VAS. Overall severity of participant's skin pain from Psoriasis is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (pain as severe as you can imagine). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline on Quick Inventory of Depressive Symptomatology-Self Report (16 Items) (QIDS-SR16)
QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. Whereas 0-5 indicates no symptoms. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS)
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, lower scores = more disability, higher scores = less disability and better health. In this study, the SF-36 acute version was used, which has a 1-week recall period. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Scores
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, lower scores = more disability, higher scores = less disability and better health. In this study, the SF-36 acute version was used, which has a 1-week recall period. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline on Patient's Global Assessment (PatGA) of Disease Severity
The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline on the Psoriasis Skin Appearance Bothersomeness (PSAB) Total Score
PSAB measure is a 3-item scale designed to measure the degree of bothersomeness of skin appearance due to Ps in participants with Ps. Participants are asked to indicate on 3 numeric rating scales (NRS) from 0 (not at all bothered) to 10 (extremely bothered) how bothered they are by any redness or discoloration, thickness, and scaling or flaking on their skin due to Ps. The scores from the 3 NRS items are summed for a total score ranging from 0 to 30, where 0 indicating no bothersomeness and 30 indicating greater bothersomeness. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline on the Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA-CLIN) Total Score
NAPPA is a clinical and participant-reported outcomes tool, and consists of 3 components: a questionnaire assessing nail-specific quality of life NAPPA-QoL (Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life), a 2-part questionnaire assessing participant relevant needs and treatment benefits NAPPA-PBI (Nail Assessment in Psoriasis and Psoriatic Arthritis - Patient Benefit Index), and a clinical assessment of objective finger nail psoriasis severity NAPPA-CLIN. Sum of all assessed finger and toes ranging between 0 (no involvement) to 16 (worst involvement). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D) + Bolt On UK Population-based Index Score
The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of a descriptive system of the respondent's health which comprises the following 5 dimensions: 1) mobility 2) self-care 3) usual activities 4) pain/discomfort 5) anxiety/depression. The EQ-5D-5L health states were converted into a single summary index by applying a crosswalk using a United Kingdom (UK) Population value set to each of the levels in each dimension. This produced participant-level index scores between -0.594 and 1.0 (worse to better health). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Psoriasis (PSO) Index Score
The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of a descriptive system of the respondent's health which comprises the following 5 dimensions: 1) mobility 2) self-care 3) usual activities 4) pain/discomfort 5) anxiety/depression. The Bolt On PSO is an addition to the EQ-5D-5L that consists of 2 dimensions specific to psoriatic disease: 6) skin irritation (itching) and 7) self-confidence. Index scores for the Bolt On PSO range from 0.0042 to 1.0 (worse to better health). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Visual Analog Scale Score
The EQ-5D 5L is a standardized measure of health status that includes a descriptive system of the respondent's health and a rating of his/her current health state using a 0 (worst health imaginable)- to 100 (best health imaginable)-millimeter (mm) Visual Analog Scale (VAS). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Absenteeism Score
The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Presenteeism Score
The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Impairment in Activities Performed Outside of Work
The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Overall Work Impairment Score
The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
Time frame: Baseline, Week 24
Percentage of Participants With Positive Responses to Neck/Face Psoriasis Question
Studying psoriasis involvement in the face, neck, and the genitals is of considerable interest for participants. These are locations that bear high potential for stigmatization and/or psychological distress, and, hence, effects in those regions are assumed to heavily influence participant's quality of life. Following set of binary questions were asked to check the satisfaction of participants. 1. Does the participant currently have visible psoriasis on face/neck? (Yes/No) 2. Does the participant currently have psoriasis on the genital area? (Yes/No)
Time frame: Week 24
Percentage of Participants Positive Responses to Genital Psoriasis Question
Studying psoriasis involvement in the face, neck, and the genitals is of considerable interest for participants. These are locations that bear high potential for stigmatization and/or psychological distress, and, hence, effects in those regions are assumed to heavily influence participant's quality of life. Following set of binary questions were asked to check the satisfaction of participants. 1. Does the patient currently have visible psoriasis on face/neck? (Yes/No) 2. Does the patient currently have psoriasis on the genital area? (Yes/No) The genital area includes the labia majora (hair-bearing), labia minora modified mucus membrane, and perineum in female patients; and the penis glans, penis - shaft, and scrotum in male patients.
Time frame: Week 24
Mean Adherence on Medication and Satisfaction With Therapy (STAQ)
Systemic Therapy Adherence Questionnaire (STAQ) is a 38 item questionnaire that was developed by shortening and adapting the Topical Treatment Adherence Questionnaire (TTAQ) for administration to participants under systemic therapy. The following STAQ items are of special interest for this study. 1. STAQ item 13 (The treatment does not affect my sex life) 2. STAQ item 16 (I am enjoying life again as a result of the treatment) 3. STAQ item 20 (The side effects of the treatment were acceptable) 4. STAQ item 31 (I am satisfied with the efficacy of the treatment) 5. STAQ item 32 (I am satisfied with the tolerability of the treatment) 6. STAQ item 35 (The positive aspects of the treatment outweigh the negative ones). The STAQ items are on a 4-point Likert scale with scores between 0 (strong disagreement) and 3 (strong agreement). LS mean was calculated using ANCOVA with term for treatment.
Time frame: Week 24
Treatment Period (Weeks 0 to 24), Extension Period (Weeks 24 to 36) followed by post-treatment follow-up period occurring from last treatment visit (week 36), or Early Termination Visit (ETV) up to a minimum of 12 weeks following that visit.
| Milestone | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Started | 54 | 54 | 54 |
| Received at least 1 dose of study drug | 54 | 52 | 52 |
| Completed | 50 | 23 | 49 |
| Not completed | 4 | 31 | 5 |
| Withdrew: Adverse event | 2 | 20 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 8 | 3 |
| Milestone | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Started | 48 | 19 | 31 |
| Completed | 45 | 18 | 29 |
| Not completed | 3 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 |
| Withdrew: Missing | 1 | 0 | 0 |
| Milestone | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Started | 41 | 26 | 46 |
| Completed | 36 | 18 | 38 |
| Not completed | 5 | 8 | 8 |
| Withdrew: Lost to follow-up | 3 | 1 | 2 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 | 5 |
| Withdrew: Adverse event | 1 | 5 | 0 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| Percentage of Participants | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) at Week 24 | 90.7 | 22.2 | 70.4 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| Percentage of Participants | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) From Baseline | 79.6 | 9.3 | 38.9 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).
| Percentage of Participants | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100) From Baseline | 40.7 | 3.7 | 13.0 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). LS mean change from baseline in PASI was calculated using Analysis of Covariance (ANCOVA) with modified Baseline- Observation- Carried Forward (mBOCF) and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline in PASI Total Score | -16.68 (-18.46 to -14.91) | -4.93 (-6.78 to -3.09) | -14.61 (-16.42 to -12.80) |
The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
| Percentage of Participants | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment (sPGA) (0,1) and ≥2 Point Improvement From Baseline Among Those With sPGA Score ≥3 at Baseline | 86.5 | 13.2 | 51.9 |
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5-point change from baseline is considered clinically relevant.
| Percentage of Participants | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Percentage of Participants Achieving DLQI (0,1) | 63.0 | 14.8 | 37.0 |
The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment), and a 5-point change from baseline is considered clinically relevant. LS mean change from baseline in DLQI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline on Dermatology Life Quality Index (DLQI) Total Score | -13.08 (-14.56 to -11.61) | -5.37 (-6.88 to -3.86) | -12.81 (-14.32 to -11.29) |
The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| % Body Surface Affected | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis | -20.64 (-23.21 to -18.08) | -5.26 (-7.93 to -2.60) | -18.46 (-21.08 to -15.85) |
The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS mean change from baseline in PPASI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline in Palmoplantar Psoriasis Severity Index (PPASI) Total Score | -7.23 (-10.88 to -3.59) | -2.45 (-6.03 to 1.13) | -3.77 (-8.10 to 0.56) |
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS mean change from baseline in PSSI was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Total Score | -20.85 (-23.63 to -18.06) | -6.76 (-9.58 to -3.94) | -18.56 (-21.35 to -15.78) |
The PBI assessment consists of 2 steps: before treatment, every patient defines his/her treatment needs according to a standardized list (Patient Needs Questionnaire \[PNQ\]). After treatment, the patient rates the degree of benefits achieved (Patient Benefits Questionnaire \[PBQ\]). 25 items are rated on a 5-point scale with values from 0 (not at all) to 4 (very), allowing for "did not apply to me" (5) and missing. For each treatment goal the PNQ importance is derived by dividing the respective PNQ item by the sum of all PNQ items. The weighted sum of each PBQ item with its respective PNQ importance yields the PBI score. LS mean was calculated using ANCOVA with LOCF and with a term for treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Patient Benefit Index (PBI) Overall Benefit Score | 3.42 (2.99 to 3.84) | 2.33 (1.81 to 2.84) | 2.66 (2.23 to 3.10) |
The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis (Ps) is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline on Itch Numeric Rating Scale (NRS) Score | -5.25 (-5.89 to -4.61) | -1.50 (-2.15 to -0.84) | -4.40 (-5.05 to -3.76) |
The pain VAS is a participant-administered single-item scale designed to measure Skin pain from Psoriasis using a 100 millimeter (mm) horizontal VAS. Overall severity of participant's skin pain from Psoriasis is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (pain as severe as you can imagine). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| Millimeter (mm) | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline on the Skin Pain Visual Analog Scale (VAS) | -33.83 (-39.46 to -28.20) | -7.20 (-12.99 to -1.42) | -28.29 (-33.98 to -22.60) |
QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity. Whereas 0-5 indicates no symptoms. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline on Quick Inventory of Depressive Symptomatology-Self Report (16 Items) (QIDS-SR16) | -2.16 (-3.00 to -1.32) | -1.01 (-1.89 to -0.14) | -2.50 (-3.37 to -1.64) |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, lower scores = more disability, higher scores = less disability and better health. In this study, the SF-36 acute version was used, which has a 1-week recall period. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) | 4.45 (2.29 to 6.60) | 0.57 (-1.64 to 2.77) | 4.01 (1.83 to 6.19) |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, lower scores = more disability, higher scores = less disability and better health. In this study, the SF-36 acute version was used, which has a 1-week recall period. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Scores | 7.13 (4.99 to 9.27) | 3.39 (1.19 to 5.59) | 6.99 (4.80 to 9.17) |
The PatGA is a single-item self-reported instrument asking the participant to rate the severity of their psoriasis "today" by circling a number on the numeric rating scale from 0 (Clear = no psoriasis) to 5 (Severe = the worst their psoriasis has ever been). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline on Patient's Global Assessment (PatGA) of Disease Severity | -3.12 (-3.47 to -2.78) | -0.87 (-1.23 to -0.51) | -2.39 (-2.75 to -2.04) |
PSAB measure is a 3-item scale designed to measure the degree of bothersomeness of skin appearance due to Ps in participants with Ps. Participants are asked to indicate on 3 numeric rating scales (NRS) from 0 (not at all bothered) to 10 (extremely bothered) how bothered they are by any redness or discoloration, thickness, and scaling or flaking on their skin due to Ps. The scores from the 3 NRS items are summed for a total score ranging from 0 to 30, where 0 indicating no bothersomeness and 30 indicating greater bothersomeness. LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline on the Psoriasis Skin Appearance Bothersomeness (PSAB) Total Score | -19.87 (-22.38 to 17.36) | -5.18 (-7.82 to -2.54) | -15.05 (-17.67 to -12.43) |
NAPPA is a clinical and participant-reported outcomes tool, and consists of 3 components: a questionnaire assessing nail-specific quality of life NAPPA-QoL (Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life), a 2-part questionnaire assessing participant relevant needs and treatment benefits NAPPA-PBI (Nail Assessment in Psoriasis and Psoriatic Arthritis - Patient Benefit Index), and a clinical assessment of objective finger nail psoriasis severity NAPPA-CLIN. Sum of all assessed finger and toes ranging between 0 (no involvement) to 16 (worst involvement). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline on the Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA-CLIN) Total Score | -6.58 (-8.12 to -5.04) | -0.14 (-1.91 to 1.62) | -3.41 (-5.30 to -1.52) |
The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of a descriptive system of the respondent's health which comprises the following 5 dimensions: 1) mobility 2) self-care 3) usual activities 4) pain/discomfort 5) anxiety/depression. The EQ-5D-5L health states were converted into a single summary index by applying a crosswalk using a United Kingdom (UK) Population value set to each of the levels in each dimension. This produced participant-level index scores between -0.594 and 1.0 (worse to better health). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D) + Bolt On UK Population-based Index Score | 0.15 (0.11 to 0.20) | 0.04 (-0.01 to 0.09) | 0.15 (0.10 to 0.20) |
The European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of a descriptive system of the respondent's health which comprises the following 5 dimensions: 1) mobility 2) self-care 3) usual activities 4) pain/discomfort 5) anxiety/depression. The Bolt On PSO is an addition to the EQ-5D-5L that consists of 2 dimensions specific to psoriatic disease: 6) skin irritation (itching) and 7) self-confidence. Index scores for the Bolt On PSO range from 0.0042 to 1.0 (worse to better health). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Psoriasis (PSO) Index Score | 0.15 (0.12 to 0.18) | 0.05 (0.01 to 0.08) | 0.13 (0.10 to 0.16) |
The EQ-5D 5L is a standardized measure of health status that includes a descriptive system of the respondent's health and a rating of his/her current health state using a 0 (worst health imaginable)- to 100 (best health imaginable)-millimeter (mm) Visual Analog Scale (VAS). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| Millimeter (mm) | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" - Visual Analog Scale Score | 16.91 (12.23 to 21.59) | 6.08 (1.21 to 10.96) | 13.91 (9.14 to 18.69) |
The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Absenteeism Score | 3.08 (-3.79 to 9.96) | -1.26 (-7.69 to 5.17) | 0.06 (-5.49 to 5.62) |
The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Presenteeism Score | -22.70 (-28.73 to -16.66) | -5.29 (-11.10 to 0.52) | -20.32 (-25.51 to -15.13) |
The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Impairment in Activities Performed Outside of Work | -28.23 (-33.99 to -22.47) | -3.45 (-9.38 to 2.47) | -23.57 (-29.58 to -17.55) |
The WPAI-PSO consists of 6 questions to determine employment status, hours missed from work because of psoriasis, hours missed from work for other reasons, hours actually worked, the degree to which psoriasis affected work productivity while at work, and the degree to which psoriasis affected activities outside of work. Four scores are derived: percentage of absenteeism, percentage of presenteeism (reduced productivity while at work), an overall work impairment score that combines absenteeism and presenteeism, and percentage of impairment in activities performed outside of work. Each WPAI score is expressed as impairment percentages (0-100), where 0 (no impairement) and 100 (greater impairment). LS mean change from baseline was calculated using ANCOVA with mBOCF and with terms for baseline and treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO), Overall Work Impairment Score | -18.20 (-26.29 to -10.11) | -6.20 (-13.66 to 1.27) | -19.80 (-26.31 to -13.29) |
Studying psoriasis involvement in the face, neck, and the genitals is of considerable interest for participants. These are locations that bear high potential for stigmatization and/or psychological distress, and, hence, effects in those regions are assumed to heavily influence participant's quality of life. Following set of binary questions were asked to check the satisfaction of participants. 1. Does the participant currently have visible psoriasis on face/neck? (Yes/No) 2. Does the participant currently have psoriasis on the genital area? (Yes/No)
| Percentage of Participants | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Percentage of Participants With Positive Responses to Neck/Face Psoriasis Question | 81.8 | 26.5 | 66.7 |
Studying psoriasis involvement in the face, neck, and the genitals is of considerable interest for participants. These are locations that bear high potential for stigmatization and/or psychological distress, and, hence, effects in those regions are assumed to heavily influence participant's quality of life. Following set of binary questions were asked to check the satisfaction of participants. 1. Does the patient currently have visible psoriasis on face/neck? (Yes/No) 2. Does the patient currently have psoriasis on the genital area? (Yes/No) The genital area includes the labia majora (hair-bearing), labia minora modified mucus membrane, and perineum in female patients; and the penis glans, penis - shaft, and scrotum in male patients.
| Percentage of participants | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| Percentage of Participants Positive Responses to Genital Psoriasis Question | 85.0 | 29.2 | 75.0 |
Systemic Therapy Adherence Questionnaire (STAQ) is a 38 item questionnaire that was developed by shortening and adapting the Topical Treatment Adherence Questionnaire (TTAQ) for administration to participants under systemic therapy. The following STAQ items are of special interest for this study. 1. STAQ item 13 (The treatment does not affect my sex life) 2. STAQ item 16 (I am enjoying life again as a result of the treatment) 3. STAQ item 20 (The side effects of the treatment were acceptable) 4. STAQ item 31 (I am satisfied with the efficacy of the treatment) 5. STAQ item 32 (I am satisfied with the tolerability of the treatment) 6. STAQ item 35 (The positive aspects of the treatment outweigh the negative ones). The STAQ items are on a 4-point Likert scale with scores between 0 (strong disagreement) and 3 (strong agreement). LS mean was calculated using ANCOVA with term for treatment.
| units on a scale | Ixekizumab | Fumaric Acid Esters | Methotrexate |
|---|---|---|---|
| STAQ item 13 | 2.84 (2.68 to 3.00) | 2.75 (2.51 to 2.99) | 2.78 (2.61 to 2.94) |
| STAQ item 16 | 2.82 (2.60 to 3.04) | 2.00 (1.68 to 2.32) | 2.43 (2.20 to 2.66) |
| STAQ item 20 | 2.76 (2.51 to 3.01) | 2.00 (1.66 to 2.34) | 2.42 (2.17 to 2.66) |
| STAQ item 31 | 2.88 (2.68 to 3.08) | 2.09 (1.79 to 2.39) | 2.29 (2.09 to 2.50) |
| STAQ item 32 | 2.86 (2.66 to 3.05) | 1.95 (1.66 to 2.25) | 2.50 (2.30 to 2.70) |
| STAQ item 35 | 2.80 (2.58 to 3.02) | 2.14 (1.82 to 2.46) | 2.53 (2.31 to 2.75) |
Collected over Up to 48 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixekizumab-Treatment Period | — | 1/54 (1.9%) | 37/54 (68.5%) |
| Fumaric Acid Esters-Treatment Period | — | 3/52 (5.8%) | 39/52 (75%) |
| Methotrexate-Treatment Period | — | 1/52 (1.9%) | 38/52 (73.1%) |
| Ixekizumab-Extension Period | — | 3/48 (6.3%) | 24/48 (50%) |
| Fumaric Acid Esters-Extension Period | — | 1/19 (5.3%) | 15/19 (78.9%) |
| Methotrexate-Extension Period | — | 4/31 (12.9%) | 18/31 (58.1%) |
| Follow-up Period | — | 4/113 (3.5%) | 0/113 (0%) |
| Event | Ixekizumab-Treatment Period | Fumaric Acid Esters-Treatment Period | Methotrexate-Treatment Period | Ixekizumab-Extension Period | Fumaric Acid Esters-Extension Period | Methotrexate-Extension Period | Follow-up Period |
|---|---|---|---|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/54 | 0/52 | 0/52 | 0/48 | 0/19 | 2/31 | 0/113 |
| Infected dermal cystInfections and infestations | 0/54 | 0/52 | 0/52 | 0/48 | 1/19 | 0/31 | 0/113 |
| Anogenital wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/54 | 0/52 | 0/52 | 0/48 | 0/19 | 1/31 | 0/113 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 0/54 | 0/52 | 0/52 | 0/48 | 0/19 | 1/31 | 0/113 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/54 | 1/52 | 0/52 | 1/48 | 0/19 | 0/31 | 0/113 |
| Invasive lobular breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/54 | 0/52 | 0/52 | 1/48 | 0/19 | 0/31 | 0/113 |
| Pancreatic neuroendocrine tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/54 | 0/52 | 0/52 | 1/48 | 0/19 | 0/31 | 0/113 |
| Abdominal painGastrointestinal disorders | 0/54 | 0/52 | 1/52 | 0/48 | 0/19 | 0/31 | 0/113 |
| ColitisGastrointestinal disorders | 0/54 | 1/52 | 0/52 | 0/48 | 0/19 | 0/31 | 0/113 |
| Gastritis erosiveGastrointestinal disorders | 0/54 | 0/52 | 1/52 | 0/48 | 0/19 | 0/31 | 0/113 |
| Event | Ixekizumab-Treatment Period | Fumaric Acid Esters-Treatment Period | Methotrexate-Treatment Period | Ixekizumab-Extension Period | Fumaric Acid Esters-Extension Period | Methotrexate-Extension Period | Follow-up Period |
|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/54 | 24/52 | 6/52 | 1/48 | 1/19 | 1/31 | 0/113 |
| NasopharyngitisInfections and infestations | 20/54 | 9/52 | 18/52 | 18/48 | 6/19 | 10/31 | 0/113 |
| Abdominal pain upperGastrointestinal disorders | 2/54 | 19/52 | 6/52 | 1/48 | 0/19 | 0/31 | 0/113 |
| FlushingVascular disorders | 0/54 | 13/52 | 0/52 | 0/48 | 0/19 | 0/31 | 0/113 |
| Injection site reactionGeneral disorders | 7/54 | 0/52 | 0/52 | 1/48 | 3/19 | 6/31 | 0/113 |
| HeadacheNervous system disorders | 7/54 | 4/52 | 9/52 | 1/48 | 1/19 | 2/31 | 0/113 |
| FatigueGeneral disorders | 4/54 | 3/52 | 8/52 | 0/48 | 1/19 | 0/31 | 0/113 |
| Injection site erythemaGeneral disorders | 0/54 | 0/52 | 0/52 | 0/48 | 2/19 | 3/31 | 0/113 |
| Injection site swellingGeneral disorders | 0/54 | 0/52 | 0/52 | 0/48 | 2/19 | 3/31 | 0/113 |
| Tinea pedisInfections and infestations | 2/54 | 0/52 | 1/52 | 1/48 | 2/19 | 0/31 | 0/113 |
All randomized participants who had baseline data.
| Age, Continuous(Years) | Ixekizumab | Fumaric Acid Esters | Methotrexate | Total |
|---|---|---|---|---|
| Mean | 44.3 ± 13.84 | 43.1 ± 14.16 | 38.7 ± 12.90 | 42.1 ± 13.77 |
| Sex: Female, Male(Participants) | Ixekizumab | Fumaric Acid Esters | Methotrexate | Total |
|---|---|---|---|---|
| Female | 12 | 11 | 18 | 41 |
| Male | 42 | 43 | 36 | 121 |
| Race (NIH/OMB)(Participants) | Ixekizumab | Fumaric Acid Esters | Methotrexate | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 43 | 44 | 42 | 129 |
| More than one race | 10 | 10 | 9 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Ixekizumab | Fumaric Acid Esters | Methotrexate | Total |
|---|---|---|---|---|
| Germany | 54 | 54 | 54 | 162 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2016 to primary completion in Nov 2016, 10 months.
Results were first posted in Jul 2018, 1 year 7 months after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 10 months is below that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab